ClearPoint Neuro (NASDAQ:CLPT) Hits New 52-Week High - Here's What Happened

Key Points

• ClearPoint Neuro's stock reached a new 52-week high of $25.75 during trading, closing at $25.05, indicating significant market interest with a volume of over 1.8 million shares traded.
• Equities analysts have issued a consensus rating of "Buy" for ClearPoint Neuro, with target prices increasing, notably from Stifel Nicolaus raising it from $8.00 to $9.00.
• The company reported a quarterly EPS of ($0.21), missing expectations slightly but achieving revenues of $9.22 million, just above analysts' forecasts.

ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) shares reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $25.75 and last traded at $25.05, with a volume of 1889067 shares trading hands. The stock had previously closed at $20.91.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wall Street Zen raised ClearPoint Neuro from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. Stifel Nicolaus boosted their target price on ClearPoint Neuro from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $19.67.

ClearPoint Neuro Stock Performance

The stock has a market capitalization of $712.17 million, a PE ratio of -30.93 and a beta of 1.19. The business has a 50 day moving average price of $12.30 and a 200 day moving average price of $12.35. The company has a debt-to-equity ratio of 1.46, a current ratio of 7.30 and a quick ratio of 6.45.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%.The company had revenue of $9.22 million during the quarter, compared to analysts' expectations of $9.20 million. ClearPoint Neuro has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Osaic Holdings Inc. lifted its holdings in shares of ClearPoint Neuro by 119.8% during the second quarter. Osaic Holdings Inc. now owns 7,705 shares of the company's stock valued at $92,000 after purchasing an additional 4,200 shares in the last quarter. Man Group plc lifted its holdings in shares of ClearPoint Neuro by 17.4% during the second quarter. Man Group plc now owns 71,884 shares of the company's stock valued at $858,000 after purchasing an additional 10,674 shares in the last quarter. Engineers Gate Manager LP bought a new position in shares of ClearPoint Neuro during the second quarter valued at $219,000. BNP Paribas Financial Markets lifted its holdings in shares of ClearPoint Neuro by 2,435.2% during the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company's stock valued at $27,000 after purchasing an additional 2,143 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of ClearPoint Neuro by 315.0% during the second quarter. Bank of America Corp DE now owns 113,698 shares of the company's stock valued at $1,358,000 after purchasing an additional 86,304 shares in the last quarter. 30.08% of the stock is owned by institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.